DSIP and the Stress Axis: Cortisol and ACTH Research
What DSIP is, and what it is not
DSIP, generic name emideltide, is a nonapeptide first isolated from the blood of rabbits during cross-perfusion sleep studies in the 1970s. It circulates in wellness and longevity markets as an injectable research peptide, sometimes marketed as a "master regulator" of stress hormones. It is not the same molecule as melatonin, trazodone, or zolpidem, and it has no chemical relationship to GLP-1 peptides. It has no FDA-approved indication for sleep, stress, or any other condition. For a general overview of the molecule, see what DSIP is.
Why people connect DSIP to cortisol and ACTH
The HPA axis is the body's central stress-signaling loop: the hypothalamus releases corticotropin-releasing hormone, which prompts the pituitary to secrete adrenocorticotropic hormone (ACTH), which drives the adrenal cortex to produce cortisol. Because DSIP was discovered in the context of sleep physiology, and because sleep and cortisol rhythms are tightly linked, early researchers explored whether DSIP could dampen HPA-axis output, particularly ACTH pulses and stress-induced cortisol spikes. That hypothesis is the origin of most modern marketing claims that DSIP "lowers cortisol" or "protects against burnout."
Verification required: those original studies predate the current PubMed-indexed literature reviewed for this page, and this page's evidence base does not include a citable primary source for DSIP's effect on ACTH or cortisol in humans. Readers should treat any specific numeric claim (a percentage reduction in cortisol, a stated ACTH suppression window) as unverified until a named, retrievable study is produced.
What the current cortisol and HPA-axis literature actually shows
The 2026 literature on HPA-axis function is substantial, but it is about the axis in general, not about DSIP. It is useful background for understanding why the axis matters clinically, and it illustrates how rigorous modern HPA-axis research is designed, which throws the absence of comparable DSIP data into relief.
- Cortisol dysregulation is implicated as a contributing factor in neurodegenerative disease processes, with proposed drug targets under active review (cortisol dysregulation and neurodegeneration).
- Insomnia symptoms interact with stress exposure in ways that relate to Alzheimer's disease biomarkers, reinforcing that sleep and the stress axis are biologically entangled (insomnia, stress, and Alzheimer's biomarkers).
- Mild autonomous cortisol secretion has measurable cognitive, structural, and functional brain correlates, an example of how even subclinical HPA-axis excess is being mapped in current research (mild autonomous cortisol secretion and brain function).
- Mindfulness-based stress reduction shows a measurable, if modest, effect on cortisol regulation across a systematic review and meta-analysis, which is the level of evidence (aggregated RCTs) that a credible HPA-axis intervention claim should be able to produce (mindfulness-based stress reduction and cortisol).
- Hydrocortisone, an FDA-approved corticosteroid, has been studied in a case report for secondary PTSD prevention, illustrating that even an approved, well-characterized HPA-axis drug is still being evaluated cautiously at the individual-case level (hydrocortisone for secondary PTSD prevention).
- Immune signatures associated with human adrenocortical hypertension and the diagnostic performance of machine-learning models in Cushing's syndrome both show how granular and methodologically careful current adrenal-axis research has become (immune signatures in adrenocortical hypertension; machine learning models in Cushing's syndrome diagnosis).
None of these papers study DSIP. They are cited here only to show what the evidentiary bar looks like for a legitimate HPA-axis claim, and to make clear that DSIP has not cleared that bar in the sources available for this page.
Does DSIP have any measured effect on cortisol or ACTH in humans?
Based on the verified evidence available for this page, no. There is no 2026 peer-reviewed human trial in this evidence set measuring DSIP's effect on cortisol, ACTH, or any other HPA-axis biomarker. That absence is itself informative: an active, well-funded field of HPA-axis research exists, running randomized trials, systematic reviews, and biomarker studies on other interventions, and DSIP does not appear in it. Anyone claiming a specific cortisol-lowering percentage for DSIP is going beyond what current literature supports, and readers should ask for the specific study, journal, and year rather than accepting an unlinked claim.
Regulatory status, dated
As of the FDA's Category 2 bulk drug substances page (content current 04/22/2026), DSIP's nomination for the 503A compounding bulks list was withdrawn by the nominators, not approved or denied on safety grounds (FDA Category 2 bulk substances list). Withdrawal is not the same as approval, and DSIP does not appear on the FDA's 503A bulk substances list, so no compounding pharmacy has enforcement-discretion cover to prepare it under that framework (503A bulk substances framework). On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee met and voted against recommending emideltide (DSIP) for the 503A bulks list (meeting record). This is a regulatory setback, not a pending approval, and readers should not interpret the committee meeting as forward momentum toward legal compounded access. For current status across peptides, see the FDA Peptide Status Tracker and the dedicated DSIP FDA status page.
What this means if you're using DSIP for stress or sleep
If someone is using DSIP hoping to blunt a stress response or lower cortisol, the honest answer is that this specific effect has not been demonstrated in the literature reviewed here, the product has no FDA-approved indication, and any batch obtained through a compounding source is currently outside the legal 503A bulks framework. That does not prove DSIP is inert or unsafe; it means the claim is unverified, not disproven. For a broader look at what evidence does and does not support across all proposed DSIP uses, see DSIP evidence quality and DSIP for sleep evidence. If the reader's real goal is symptom relief for insomnia or chronic stress, FDA-approved and guideline-supported options exist and should be discussed with a clinician before considering an unapproved peptide; comparisons are available at DSIP vs. prescription sleep aids.
Evidence boundary: what is established, plausible, and not established
| Claim category | Status | What supports it |
|---|---|---|
| The HPA axis governs cortisol and ACTH release and is measurable with validated tests | Established | General endocrinology; illustrated in this evidence set by adrenal and cortisol-testing studies such as the ACTH stimulation test data in dogs, used here only to show test methodology, not a DSIP finding |
| Sleep disruption and HPA-axis dysregulation are biologically linked | Established | Insomnia, stress exposure, and Alzheimer's biomarkers |
| Behavioral interventions (mindfulness, sound-based meditation) can modestly shift cortisol | Established, modest effect size | Mindfulness-based stress reduction meta-analysis; sound-based meditation RCT |
| DSIP historically was hypothesized to inhibit ACTH release | Historical hypothesis only | No citable source in this evidence set; verification required before restating as fact |
| DSIP measurably lowers cortisol or ACTH in humans at any specific dose | Not established | No trial data available in the sources reviewed for this page |
| DSIP is FDA-approved or lawfully compoundable under 503A | Not established, and currently rejected | FDA Category 2 page; advisory committee meeting |
When to seek clinical evaluation instead of self-treating
Cortisol dysregulation can be a sign of an underlying endocrine disorder, not something to self-manage with an unapproved peptide. Symptoms such as unexplained weight change, new hypertension, muscle wasting, persistent fatigue, or mood changes alongside sleep disruption warrant an evaluation for conditions like Cushing's syndrome or adrenal insufficiency, which have established diagnostic pathways (diagnostic model comparisons in Cushing's syndrome). A clinician can order the appropriate cortisol and ACTH testing; a peptide bought without a prescription cannot substitute for that workup.